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Natural killer cells are an integral part of the immune system and represent a large
proportion of the lymphocyte population in the liver. The activity of these cells is regulated
by various cell surface receptors, such as killer Ig-like receptors (KIR) that bind to
human leukocyte antigen (HLA) class I ligands on the target cell. The composition of
KIR receptors has been suggested to influence the development of specific diseases,
in particularly autoimmune diseases, cancer and reproductive diseases. The role played
in idiosyncratic drug-induced liver injury (DILI) is currently unknown. In this study, we
examined KIR gene profiles and HLA class I polymorphisms in amoxicillin-clavulanate
(AC) DILI patients in search for potential risk associations. One hundred and two AC
DILI patients and 226 controls were genotyped for the presence or absence of 16 KIR
loci, including the two pseudogenes 2DP1 and 3DP1. No significant differences were
found in the distribution of individual KIRs between patients and controls, which were
comparable to previously reported KIR data from ethnically similar cohorts. The 21.6
and 21.2% of the patients and controls, respectively, were homozygous haplotype A
carriers, while 78.4 and 78.8%, respectively, contained at least one B haplotype (Bx).
The genotypes translated into 27 (AC DILI) and 46 (controls) different gene profiles,
with 19 being present in both groups. The most frequent Bx gene profile containing
KIRs 2DS2, 2DL2, 2DL3, 2DP1, 2DL1, 3DL1, 2DS4, 3DL2, 3DL3, 2DL4, and 3PD1
was present in 16% of the DILI patients and 14% of the controls. The distribution of
HLA class I epitopes did not differ significantly between AC DILI patients and controls.
The most frequent receptor-ligand combinations in the DILI patients were 2DL3 +
epitope C1 (67%) and 3DL1 + Bw4 motif (67%), while 2DL1 + epitope C2 (69%)
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and 3DL1 + Bw4 motif (69%) predominated in the controls. This is to our knowledge
the first analysis of KIR receptor-HLA ligand associations in DILI, although our findings
do not support evidence of these genetic variations playing a major role in AC DILI
development.
Keywords: hepatotoxicity, drug-induced liver injury, pharmacogenetics, immune response, HLA, receptor/ligand
INTRODUCTION
Idiosyncratic drug-induced liver injury (DILI) is a condition that
symptomatically can mimic most kinds of acute and chronic
liver disorders. Unlike intrinsic DILI, it cannot be predicted
based on drug pharmacological action or dose. It is believed
that idiosyncratic DILI occurs in one of every 10 000 to 100
000 patients taking a specific medication, with some drugs
being more prone to cause DILI than others. The majority of
idiosyncratic DILI cases fully recuperates after drug cessation,
while 4–10% go on to develop acute liver failure (Björnsson
and Olsson, 2005; Robles-Diaz et al., 2014). Furthermore, DILI
is a major factor in drug development discontinuations and
postmarketing drug withdrawals. Despite increased interest, the
cellular mechanism behind DILI is not fully understood. Previous
studies have, however, demonstrated an apparent role for the
immune system in various forms of idiosyncratic DILI, including
higher representation of specific HLA class I and II alleles in
amoxicillin-clavulanate (AC) DILI patients (Lucena et al., 2011;
Stephens et al., 2013; Grove and Aithal, 2015).
Natural killer (NK) cells are an integral part of the innate
immune system, in particularly in the liver, with cytolytic capacity
to kill cancer and infected cells. Furthermore, NK cells can
contribute to inflammation and immunoregulation through their
release of cytokines and subsequently also play a modifying
role in adaptive immunity. The activity of NK cells is regulated
by various types of cell surface receptors, such as killer Ig-
like receptors (KIR). The KIR family contains both inhibitory
(iKIR: 2DL1, 2DL2, 2DL3, 2DL4, 2DL5, 3DL1, 3DL2, and 3DL3)
and activating (aKIR: 2DS1, 2DS2, 2DS3, 2DS4, 2DS5, and
3DS1) receptors. Although initially believed to be an inhibitory
receptor, KIR2DL4 is now considered to have both inhibitory
and activating signaling domains (Moradi et al., 2015). The
KIR genes are highly variable, with polymorphisms on gene as
well as allele levels. Both aKIRs and iKIRs are expressed on
the same NK cell and the exact KIR composition varies from
individual to individual. The KIR genes are generally inherited
as haplotype A or B. Group A comprises six iKIRs (2DL1,
2DL3, 2DL4, 3DL1, 3DL2, and 3DL3), one aKir (2DS4) and two
pseudogenes (2DP1 and 3DP1). Any other KIR gene combination
with at least one of the KIR2DL2, 2DL5, 3DS1, 2DS1, 2DS2,
2DS3, or 2DS5 genes present, is referred to as group B haplotype
(Uhrberg et al., 1997). The balance of activating and inhibitory
KIRs may subsequently contribute to enhanced risk of distinct
diseases.
Inhibitory NK cell activity signals are mainly induced through
the recognition of HLA class I ligands by iKIR receptors.
KIR2DL1 binds preferentially to HLA-C allotypes characterized
by a lysine in amino acid position 80 (C2 epitope), while
KIR2DL3 and particularly 2DL2 have higher recognition affinity
for the C1 epitope, containing an asparagine in the same position
(Winter and Long, 1997; Moesta et al., 2008). The HLA-B alleles
can be divided into allotypes containing the serological Bw4 or
Bw6 public epitope, with the exception of a few B alleles that
do not contain either of these epitopes (Gumperz et al., 1997).
KIR3DL1 binds preferentially to HLA-B allotypes characterized
by the Bw4 epitope, which is defined by the amino acid motifs
at positions 77–83. The HLA-A alleles A∗23:01, A∗24:02, and
A∗32:01 have also been found to contain the Bw4 epitope and
subsequently can act as ligands for KIR3DL1. The KIR3DL2
receptor has been shown to bind to HLA-A3 and A11 allotypes,
although the interaction appears to be highly dependent on the
peptide bound to the HLA complex (Hansasuta et al., 2004).
In addition, a recent study has demonstrated that HLA-B27
can also interact with KIR3DL2, although B27 is less frequent
than the HLA-A allotypes in most populations (Shaw et al.,
2014). The aKIR receptor ligands are less well established. It
is believed that many aKIR receptors share HLA ligands with
their corresponding inhibitory counterparts, but bind with lower
affinity (Stewart et al., 2005).
The existing variability in KIR and HLA profiles between
individuals could potential result in specific profiles being more
prone to certain medical conditions, as suggested for Italian
KIR2DS1 and HLA-C2 ligand carriers being more susceptible to
autoimmune hepatitis (Littera et al., 2016). We have previously
demonstrated that HLA alleles have an effect on AC DILI
susceptibility and phenotype. As HLA class I alleles are involved
in the regulation of NK cell activity through KIR receptors, and
considering the increased abundance of NK cells in the liver,
we aimed to evaluate the contribution of HLA class I profiles
in conjunction with KIR gene repertoires to determine potential
genetic predispositions for AC DILI in Spanish subjects.
MATERIALS AND METHODS
Subjects and Study Protocol
A total of 102 AC DILI cases were selected from those submitted
to the Spanish DILI Registry, a collaborative network established
in 1994 to prospectively identify cases of DILI in a standardized
manner. The criteria for DILI at the time of subject inclusions
in the study were: an increase in alanine transaminase (ALT)
≥3 times the upper limit of normal (xULN) or ≥2 xULN of
alkaline phosphatase (ALP) or total bilirubin (TBL) ≥2 xULN
if associated with elevations of ALT or ALP. However, 91% of
the cases also fulfilled the more recent DILI criteria established
by Aithal et al. (2011): ALT ≥ 5 xULN or ALT ≥ 3 xULN +
TBL≥ 2 xULN or ALP≥ 2 xULN. The pattern of liver injury was
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classified based on R-value calculations as previously described
(Aithal et al., 2011). A detailed description of the operational
structure of the registry, data recording and case ascertainment
has been reported elsewhere (Andrade et al., 2005). As a control
group, we selected 226 unrelated Spanish subjects of Caucasian
descent, without previous DILI history. These controls were
recruited from the Spanish Bone Marrow Donor Registry as well
as hospital volunteers from the same geographic region and of
similar age and gender distribution. Due to the frequent use of
AC in the general population in Spain it was assumed that a large
proportion of the controls would have taken AC during some
stage of their lives without developing DILI.
Ethics Statement
The study protocol was approved by the local ethics committee
of the coordinating center at the Hospital Universitario Virgen de
la Victoria (Comité Ético de Investigación) in Málaga, Spain. All
subjects who took part in the study were 18 years of age or older.
All subjects gave written informed consent, which conformed
with the current Helsinki Declaration, prior to study enrolment.
DNA Extraction and Genotyping
Venous blood was obtained from each subject and DNA was
extracted using QIAamp DNA Blood Mini Kit (QIAGEN,
Hilden, Germany) according to the manufacturer’s instructions.
Genotyping of KIRs 2DL1, 2DL2, 2DL3, 2DL4, 2DL5, 3DLI, 3DL2,
3DL3, 2DS1, 2DS2, 2DS3, 2DS4, 2DS5, 3DS1, 2DP1, and 3DP1
was performed using the Lifecodes KIR-SSO typing Kit 545110R
(Immucor Inc, Norcross, GA, USA) and analyzed with a Bio-
Plex 200 system (Luminex xMAP, Austin, TX, USA) according
to the manufacturer’s instructions. Haplotype designation was
determined as previously described (Uhrberg, 2005). Individuals
carrying only haplotype A genes (KIR2DL1, 2DL3, 2DL4, 3DL1,
3DL2, 3DL3, 2DS4, 2DP1, and 3DP1) were considered as AA
genotype carriers. All other KIR gene combinations were referred
to as Bx genotypes, where x indicates an A or B haplotype.
Genotyping of the HLA class I (A, B, and C) loci was
performed using the LABType R© SSO typing test (One Lambda,
Canoga Park, CA, USA). Target DNA was amplified by PCR
using sequence-specific primers, followed by hybridization with
allele-specific oligodeoxynucleotides coupled with fluorescent
phycoerythrin-labeled microspheres. The fluorescence intensity
was determined with a Bio-Plex 200 system (Luminex xMAP,
Austin, TX, USA). HLA alleles were assigned using the HLA-
Tools software (One Lambda, Canoga Park, CA, USA). The HLA
ligand groups were assigned based on the amino acid residues
of the corresponding alleles. The HLA-C alleles containing an
asparagine at position 80 were considered as being C1 and those
with a lysine in the same position as C2. Similarly, the HLA-
B alleles were classified as HLA-Bw4 and Bw6 depending on
the amino acids at positions 77–831. In addition, HLA-A∗23:01,
A∗24:02, and A∗32:01 were also considered as Bw4 containing
alleles based on previously demonstrated results (Stern et al.,
2008).
1http://www.ufrgs.br/imunovet/molecular_immunology/hla.html
Statistical Analysis
Human leukocyte antigen allele distributions were compared
between DILI patients and controls using a comparison of
proportions test, a derivative of Fisher’s exact test, and p < 0.05
was considered to be statistically significant.
RESULTS
DILI Patient Characteristics
A total of 102 AC DILI patients were included in the study of
which 60 were males and 42 females. The mean age at DILI onset
was 59 years, ranging from 18 to 88 years. The predominant
pattern of injury, based on the R-value calculated from the first
blood sample analysis after DILI recognition, was hepatocellular
(n = 39) followed by mixed (n = 34) and cholestatic (n = 29).
Of the 102 patients two developed liver failure resulting in death
or liver transplantation. Demographics, clinical, and laboratory
parameters of the 102 DILI cases included in the study are
outlined in Table 1.
KIR Gene Distribution
All the 102 AC DILI patients and 226 controls were genotyped
for the presence or absence of 16 KIRs, including the two
pseudogenes 2DP1 and 3DP1. No significant differences were
found in the distribution of individual KIR genes between
patients and controls. The four framework genesKIR3DL2, 3DL3,
3DP1, and 2DL4 were present in all tested subjects. KIR2DL1,
3DL1, 2DS4, and 2DP1 were found in more than 90% of both the
patient and control cohorts, while 2DS1, 2DS3, 2DS5, and 3DS1
where the least present genes, only seen in less than 45% of the
TABLE 1 | Demographics, clinical, and laboratory parameters of the 102
DILI cases included in the study.
Demographics
Mean age, years (range) 59 (18–88)
Male/female, n 60/42
Body mass index, mean ± SD 26.1 ± 3.2
Time to DILI onset, n
<15 days 62
15 – 30 days 26
>30 days 14
Clinical presentation, n
Jaundice 85
Hospital admission 59
Type of liver injury, n
Hepatocellular 39
Cholestatic 29
Mixed 34
Biochemical parameters∗, mean ± SD (median)
Total bilirubin (mg/dL) 7.6 ± 5.5 (6.7)
ALT xULN, hepatocellular and mixed cases 18.0 ± 19.4 (9.8)
ALP xULN, cholestatic and mixed cases 2.7 ± 1.6 (2.2)
∗First available serum analysis after DILI onset. ALT, alanine transaminase; ALP,
alkaline phosphatase; ULN, upper limit of normal.
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) subjects (Table 2). While the KIR2DS4 gene was among the more
frequently detected genes, 46 and 51% of the KIR2DS4 carrying
DILI patients and controls, respectively, were homozygous for a
22 base pair deletion, which produces a non-functional receptor,
and 37% in both subgroups were found to be heterozygous for the
same mutation.
Among the DILI cases 21.6% were homozygous for the
A haplotype (AA genotype) while 78.4% contained a B
haplotype (Bx: AB or BB genotypes). The corresponding
genotype distribution in the control subjects were 21.2 and
78.8%, respectively. Hence, no significant difference in genotype
distribution was found between the two groups. The determined
genotypes translated into 27 different gene profiles in the DILI
patients and 46 in the controls. Nineteen of the gene profiles
were present in both groups, while 8 were specific to the DILI
patients and 27 to the controls (Figure 1). The individual
DILI-specific genotypes demonstrated frequencies of 0.1–2.0%,
while the individual control-specific genotypes had frequencies
of 0.4–2.2%. Despite the relatively low number of ‘group-specific’
genotypes, the DILI group presented a significantly smaller
proportion of individuals with DILI-specific genotypes compared
to that of controls with control-specific genotypes (8.8% vs. 19%,
p= 0.024).
None of the individual Bx genotypes present in both groups
were found to be significantly different with respect to frequency
in the DILI group compared to the controls. The most frequent
gene profile among the Bx haplotype carriers contained 3DL1,
2DL1, 2DL3, 2DS4, 2DL2, 2DS2, and 2DP1 in addition to the four
framework loci, and was present in 15.7% of the DILI patients and
14.2% of the controls (Figure 1). Of the AA haplotype carriers
with 2SD4 as the only activating receptor, 54.5% of the DILI
patients and 60.4% of the controls where homozygous for the 22
base pair deletion in the 2SD4 gene, which subsequently lead to a
haplotype without any aKIR receptor. In addition, 45.5 and 35.4%
of the DILI and control AA haplotype carriers, respectively, were
found to be heterozygous for same deletion.
Activating KIR genes have been associated with increased
susceptibility to certain diseases, in particular autoimmune
related disorders. Hence, we compared DILI patients and
controls with respect to the total number of aKIR genes in
each subject. KIR2DL4 was not included in this analysis, as it
was present in all study subjects and is believed to have both
inhibitory and activating functions. Furthermore, presence of the
22 bp deletion in exon 5 causing a truncated KIR2DS4 protein
was taken into consideration. Hence, subjects homozygous for
the deletion allele and with no other aKIR genes were considered
as having no aKIRs. One single aKIR gene was most frequently
seen among both DILI patients (21.6%) and controls (20.8%),
followed by four aKIR genes in the DILI (16.7%) and five aKIR
genes in the control group (16.4%). The presence of six aKIR
genes occurred most infrequently in both the groups, although
the proportion was slightly higher among the DILI patients
(4.9% vs. 2.6%). No statistically significant differences were found
comparing DILI patients and controls classified by total number
of aKIR genes per subject (Figure 2).
To determine any potential effects of KIR genes on disease
phenotype, the presence of KIR genes was also analyzed in the
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FIGURE 1 | KIR genotype distribution in 102 Spanish amoxicillin-clavulanate–induced liver injury patients and 226 controls. Genotype IDs refer to ID
numbers assigned by the Allele Frequency Net Database (www.allelefrequencies.net). The presence and absence of a KIR gene are indicated by a shaded and white
box, respectively.
AC DILI cohort stratified by pattern of liver injury. No significant
differences were found in the distribution of individual KIR genes
between patients presenting with hepatocellular, cholestatic and
mixed type of liver injury compared with the controls (data not
shown).
HLA Ligand Distribution
All patients and controls were genotyped for the HLA class I
loci (A, B, and C) in order to determine the distribution of
epitopes C1, C2, and Bw4 as well as the allele groups A3/A11 and
B27, which act as ligands for different KIR receptors. Phenotype
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FIGURE 2 | Total number of activating KIR genes (2DS1, 2DS2, 2DS3, 2DS4, 2DS5, and 3DS1) present in 102 Spanish amoxicillin-clavulanate–induced
liver injury patients and 226 controls. Only full-length 2DS4 is considered as an activating KIR, while the presence of 2DS4 with a 22 base pair deletion in exon 5
causing a truncated KIR2DS4 is not.
distributions of the HLA ligands are presented in Table 3. HLA
C1 was more frequent than C2 and in both DILI patients (83%
vs. 66%) and controls (78% vs. 73%), though the difference was
more pronounced among the DILI patients. Sixty percent of the
DILI patients contained at least one copy of the HLA-B Bw4
motif compared to 65% in the controls. The distribution of Bw4-
Thr80 and Bw4-Ile80 motifs was relatively equal with 36% vs.
33% in the DILI patients and 37% vs. 38% in the control subjects,
respectively. The proportion of Bw4 containing HLA-A allele
carriers was slightly higher in the control subject compared to
TABLE 3 | Phenotype distribution of HLA class I KIR ligands in 102 Spanish
amoxicillin-clavulanate–induced liver injury patients and 226 controls.
HLA class I DILI, n(%) Controls, n(%)
HLA-C1 85 (83) 176 (78)
HLA-C2 67 (66) 164 (73)
C1/C1 35 (34) 62 (27)
C2/C2 17 (17) 50 (22)
C1/C2 50 (49) 114 (50)
HLA-B Bw4 61 (60) 147 (65)
HLA-B Bw4/Bw4 18 (18) 44 (19)
HLA-B Bw4-Thr80 36 (35) 83 (37)
HLA-B Bw4-Ile80 34 (33) 85 (38)
HLA-A Bw4∗ 18 (18) 60 (27)
HLA-A3 or A11 32 (31) 59 (26)
HLA-B27 4 (3.9) 13 (5.8)
∗HLA-A∗23:01, 24:02, and 32:01.
DILI patients (27% vs. 18%), while 31% of the DILI patients
contained HLA-A3 or A11 alleles compared to 26% of the
controls. In addition to A3 and A11, B27 has also been reported
to be a potential KIR3DL2 ligand. The distribution of B27 carriers
was comparable between the two study populations (3.9% vs.
5.8%). None of the analyzed ligands differed significantly with
respect to carrier distributions between DILI cases and controls.
KIR Receptor-HLA Ligand Distributions
The KIR receptors bind to specific HLA ligands. Hence the
combination of KIR genes and corresponding HLA ligands
present in the subjects was also analyzed. The most frequently
found receptor-ligand combinations in the DILI patients were
2DL3 + C1 (67%) and 3DL1 + Bw4 motif (67%), while 2DL1
+ C2 (69%) and 3DL1 + Bw4 motif (69%) predominated in
the controls. In contrast, 2DS4 with at least one copy of the
full length gene combined with HLA A11 alleles was the least
frequently found receptor-ligand combination in both the DILI
(3.9%) and the control (4.9%) group. No significant differences in
phenotype distribution of the analyzed KIR gene and HLA ligand
combinations were found between DILI patients and controls
(Table 4).
DISCUSSION
Natural killer cells are enriched in the liver, comprising 25–40%
of intrahepatic lymphocytes in normal adult livers (Tian et al.,
2013). While these cells play an important role in liver diseases
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TABLE 4 | Phenotype distribution of KIR genes and HLA ligands in 102
Spanish DILI patients and 226 controls.
KIR + HLA ligands, n(%) DILI, n(%) Controls, n(%)
Inhibitory
2DL1 + C2 63 (62) 156 (69)
2DL2 + C1 51 (50) 108 (48)
2DL3 + C1 68 (67) 150 (66)
3DL1 + Bw4∗ 68 (67) 157 (69)
3DL1 + Bw4 (A)a 18 (18) 57 (25)
3DL1 + Bw4 (B)b 58 (57) 135 (60)
3DL1 + Bw4 Thr80 34 (33) 77 (34)
3DL1 + Bw4 Ile80b 32 (31) 77 (34)
3DL2 + A3/A11/B27 36 (35) 66 (29)
Activating
2DS1 + C2 27 (26) 61 (27)
2DS2 + C1 53 (52) 106 (47)
2DS2 + A11 6 (5.9) 23 (10.2)
2DS4# + A11 4 (3.9) 11 (4.9)
3DS1 + Bw4 motif∗ 27 (26) 62 (27)
3DS1 + Bw4 (A)a 9 (9) 25 (11)
3DS1 + Bw4 (B)b 22 (22) 52 (23)
3DS1 + Bw4 Thr80 12 (12) 30 (13)
3DS1 + Bw4 Ile80b 12 (12) 30 (13)
∗HLA-A and B alleles, aHLA-A alleles only, bHLA-B alleles only, #Homozygots and
hetrozygots for the full length allele only.
by inhibiting viral infection, tumor cell growth and liver fibrosis,
they can also be harmful causing hepatocellular damage and
inhibiting liver regeneration if not controlled properly. Impaired
regulation of NK cell activity is thought to contribute to
hepatic diseases such as autoimmune hepatitis, primary biliary
cirrhosis and sclerosing cholangitis (Tian et al., 2013). The fact
that intrahepatic NK cells exhibit higher level of cytotoxicity
and increased expression of cytotoxic mediators compared to
peripheral NK cells highlights the importance of adequate
regulation of NK cell activity (Ishiyama et al., 2006). Due to
the crucial role of KIR receptors in NK cell activity regulation,
KIR genotype analyses have been performed across various
conditions, including hepatic diseases, to elucidate the potential
contribution of KIR variability in disease susceptibility. In this
study, we have analyzed KIR and HLA polymorphisms with
regards to AC DILI susceptibility. This is to our knowledge
the first KIR analysis focusing on DILI. We did not find
any significant differences in the frequency of individual KIR
genes between DILI cases and controls. Furthermore, carrier
frequencies in the current control group were similar to those of
independent Spanish subjects previously published (Hollenbach
et al., 2010). One must also keep in mind that not only the KIR
gene repertoire varies between individuals but that each KIR gene
is also highly polymorphic. There are currently 753 different KIR
alleles in total present in the IPD-KIR database (Robinson et al.,
2005). Hence, analyzing only presence or absence of KIR genes
could obscure existing allele associations.
The presence of aKIRs is generally more variable than that of
iKIRs. It has been suggested that the total number of aKIRs could
affect disease susceptibility as augmented signals from multiple
aKIR receptors might exacerbate the activation of NK cells and
T cell subsets against self-antigens leading to disease conditions
(Ashouri et al., 2014). Hence, we compared the total number of
aKIRs in individual DILI patients and controls, but did not find
any significant differences in the proportion of subjects classified
by aKIRs, ranging from 0 to 6 different types of activating
receptors. As associations between dominant aKIR repertoires
and disease susceptibility detected to date are mainly limited
to autoimmune conditions, such as lupus erythematosus, Vogt–
Koyanagi–Harada syndrome, multiple sclerosis, Hashimoto’s
thyroiditis and autoimmune hepatitis (Hou et al., 2010; Levinson
et al., 2010; García-León et al., 2011; Ashouri et al., 2014; Littera
et al., 2016) a dominance of aKIR receptors may be less important
in AC DILI. Nevertheless, autoimmune conditions can also be
negatively associated with aKIRs as demonstrated for pemphigus
foliaceus. Here the presence of more than three aKIR genes
appears to play a protective role, which highlights the fact that
the role of aKIR dominance is not general but dependent on
the underlying mechanism of the condition in question (Augusto
et al., 2012).
Similar to the lack of association between aKIRs and DILI
susceptibility, the proportions of AA and Bx genotype carriers
were comparable between patients and controls. AA1 was the
most frequent genotype in both groups. The Bx genotypes
translated to 26 and 45 different genotypes in the DILI patients
and controls, respectively, with 18 Bx genotypes being present in
both groups with similar frequencies. The three most frequent
Bx genotypes in both the DILI and control group were Bx4,
Bx5, and Bx2, which together made up 40% and 35% of the
Bx genotype carriers in the two populations, respectively. The
individual genotype distributions of Bx4, Bx5, and Bx2 were
similar to those previously observed in different Spanish and
other European populations2. These three genotypes are also
among the most common KIR genotypes worldwide (Hollenbach
et al., 2012). In the current study, we found nine Bx genotypes
that were specific to the DILI patients and 27 that were only
found in the control groups. However, it is unlikely that the DILI-
specific genotypes would have any bigger impact on AC DILI
susceptibility due to the small number of patients that were found
to be carriers of these KIR genotypes. Similarly, the low frequency
of the individual control-specific genotypes does not speak in
favor of these genotypes having any protective effect against AC
DILI.
The function of KIR receptors depends on the presence of
appropriate HLA ligands on the target cell in order for correct
signaling and NK cell activity to occur. Hence, we analyzed
the presence of currently identified HLA class I ligands in our
patient and control cohorts but did not find any significant
differences between the two groups. HLA ligands have, however,
been associated with liver disease progression. For example,
HLA-C1 homozygosity and presence of the HLA-Bw4 I80 variant
have been associated with better overall survival of hepatitis C
virus-related hepatocellular carcinoma after curative treatment
(Cariani et al., 2013), while HLA-C2 homozygosity has been
associated with increased risk of hepatitis C virus infection
2www.allelefrequencies.net
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treatment failure (Suppiah et al., 2011). Evidence of enhanced
risk of developing primary sclerosing cholangitis in HLA-Bw6
and HLA-C1 homozygotes has also been presented (Karlsen et al.,
2007).
Considering KIR and HLA repertoires simultaneously has
likewise been explored in search for the role of NK cells in disease
conditions. Our analysis did not reveal any significant difference
in concurrent KIR receptor and HLA ligand carriage between
DILI patients and control subjects. The KIR-HLA combinations
considered in this study were based on identified ligands to
date. However, the current understanding of KIR ligands is
not complete and presently unknown KIR receptor-HLA ligand
interactions could possibly influence DILI susceptibility and
should therefore not be overlooked. Furthermore, it has been
suggested that different KIR allele products can have different
affinity for the same HLA ligand (Frazier et al., 2013), which
could lead to differences in NK cell activity regulation. As our
KIR analysis was limited to presence or absence of KIR receptors,
this aspect was consequently not evaluated.
In summary, in the first exploratory study of 102 Spanish
AC DILI cases and 226 controls no significant differences in
KIR repertoires and corresponding HLA class I ligand profiles
were detected. These results are suggestive of KIRs not being
major risk factors for AC DILI susceptibility. However, as the
mechanism of KIR receptors is not completely elucidated to date
and NK cell activity regulation systems additional to KIR are
present, a potential role for NK cells activity in DILI should not be
completely dismissed. Further studies on the level of KIR receptor
expression and cytokine production are warranted in this area.
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